These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 15383641)

  • 1. Ximelagatran: an oral direct thrombin inhibitor.
    Dager WE; Vondracek TG; McIntosh BA; Nutescu EA
    Ann Pharmacother; 2004 Nov; 38(11):1881-97. PubMed ID: 15383641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
    Harenberg J; Ingrid J; Tivadar F
    Isr Med Assoc J; 2002 Nov; 4(11):1003-5. PubMed ID: 12489490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ximelagatran: a new oral anticoagulant.
    Hrebickova L; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(6):397-408. PubMed ID: 14633322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era..
    Mohapatra R; Tran M; Gore JM; Spencer FA
    Am Heart J; 2005 Jul; 150(1):19-26. PubMed ID: 16084146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ximelagatran: an orally active direct thrombin inhibitor.
    Gulseth MP
    Am J Health Syst Pharm; 2005 Jul; 62(14):1451-67. PubMed ID: 15998925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL
    J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
    Eriksson H; Lundström T; Wåhlander K; Clason SB; Schulman S;
    Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
    Evans HC; Perry CM; Faulds D
    Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ximelagatran: a new oral anticoagulant.
    Francis CW
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):139-52. PubMed ID: 15171963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
    Halperin JL;
    Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
    Tangelder MJ; Frison L; Weaver D; Wilcox RG; Bylock A; Emanuelsson H; Held P; Oldgren J
    Am Heart J; 2008 Feb; 155(2):382-7. PubMed ID: 18215612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of ximelagatran in the treatment of venous thromboembolism.
    Schulman S
    Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():18-24. PubMed ID: 15812200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
    Andersen JC
    Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
    Albers GW;
    Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ximelagatran (AstraZeneca).
    Hopfner R
    Curr Opin Investig Drugs; 2002 Feb; 3(2):246-51. PubMed ID: 12020054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
    Koscielny J; Kiesewetter H; Jörg I; Harenberg J
    Clin Appl Thromb Hemost; 2007 Jul; 13(3):299-307. PubMed ID: 17636192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.